Literature DB >> 9331016

Long-term treatment with candesartan cilexetil does not affect glucose homeostasis or serum lipid profile in mild hypertensives with type II diabetes.

P Trenkwalder1, M Lehtovirta, K Dahl.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9331016

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN： 0950-9240            Impact factor:   3.012


× No keyword cloud information.
  6 in total

1.  RAS blockade: new possibilities in the treatment of complications of diabetes.

Authors:  L Ruilope
Journal:  Heart       Date:  2000-09       Impact factor: 5.994

2.  Candesartan cilexetil/hydrochlorothiazide treatment in high-risk patients with type 2 diabetes mellitus and microalbuminuria: the CHILI T2D study.

Authors:  Reinhard Ketelhut; Peter Bramlage
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

Review 3.  Candesartan cilexetil. A review of its use in essential hypertension.

Authors:  K J McClellan; K L Goa
Journal:  Drugs       Date:  1998-11       Impact factor: 9.546

4.  Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk (CHILI Triple T).

Authors:  Gerd Bönner; Bernhard Landers; Peter Bramlage
Journal:  Vasc Health Risk Manag       Date:  2011-02-17

Review 5.  Management of hypertension with fixed dose combinations of candesartan cilexetil and hydrochlorothiazide: patient perspectives and clinical utility.

Authors:  Thomas Mengden; Sakir Uen; Peter Bramlage
Journal:  Vasc Health Risk Manag       Date:  2009-12-29

6.  The effect of chronic candesartan therapy on the metabolic profile and renal tissue cytokine levels in the obese Zucker rat.

Authors:  Carolyn M Ecelbarger; Arjun Rash; Rajesh K Sinha; Swasti Tiwari
Journal:  Mediators Inflamm       Date:  2010-05-17       Impact factor: 4.711
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.